Oncology Venture – Latest news
Successful inclusion in Phase 2 of LiPlaCis for metastatic Breast cancer
English
Swedish
LiPlaCis Phase 2: Relevant Clinical Benefits in 3 out of 5 Treated Patients
English
Swedish
Oncology Venture publishes Half-year Report 2017
English
Swedish
Oncology Venture annonces Pipeline update
See press release
Läs pressmeddelande
2X Oncology’s chief executive officer, George O. Elston’s letter to shareholders
Read the newsletter
MedWatch article from 3 August 2017
Lovende studie bringer Oncology Venture nærmere første lægemiddel (Danish)
Oncology Venture närmar sig sitt första läkemedel efter en lovande studie (Swedish)
Aktieinfo publishes analysis on Oncology Venture
Read the analysis (Danish only)
Read the analysis (Swedish)
Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor from Eisai
Oncology Venture to evaluate Phase 3 product from Novartis
Press coverage from MedWatch media (Danish)
Press coverage from MedWatch media (Swedish)
Press release (English)
Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121
See Press release
Läs pressmeddelande
Successful prediction of Cancer response to LiPlaCis in Breast cancer and other tumors by OV’s DRP
See Press release
Läs pressmeddelande
OV`s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010
See Press release
Läs pressmeddelande
The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by the DRP
See Press release
Läs pressmeddelande
2X Oncology Inc. presents at Jefferies Global Healtcare conference (live webcast)
Berlingske Business: Interview with CEO of Oncology Venture
Read the article
Interview with OV and MPI in ‘Millionærklubben’
Listen to the radio program
Latest articles from MedWatch (Danish)
19 May 2017: MPI-test skal sparke nyt liv i gammel kemoterapi
24 March 2017: Oncology Venture indgår aftale med japanske Eisai
15 February 2017: Oncology Venture vil hente rekordbeløb
19 January 2017: Oncology Venture får europæisk stjernebevilling
VD Peter Buhl video presentation at Sedermeradagen in Copenhagen 23. March
See the Video
Oncology Venture secures seed financing for two SPVs & DRP Exclusivity
English
Swedish
Oncology Venture: First DRP-positive breast cancer patient obtained reduction of tumor
English
Swedish
Oncology Venture: Best Practice article on APO010
Download (In Danish only)
Presentation of OV by CEO Peter Buhl Jensen
Video
Smallcap.se analysis of Oncology Venture
Swedish
English
Peter Buhl Jensen talks about Oncology Venture – Radio24syv
Listen here – 10 July 2015
Listen here – 22 July 2015
Stock information
Latest (SEK)
High (SEK)
Low (SEK)
%
+/-
Volume
Amount
Updated on
DRP Technology Presentation
OV Company Presentation
(PDF-version)
